NCT02437396 is a clinical trial in Gaucher Disease Type I, sponsored by University of Minnesota.

Who is sponsoring NCT02437396?

NCT02437396 is sponsored by University of Minnesota.

What condition does NCT02437396 study?

NCT02437396 studies Gaucher Disease Type I, Oxidative Stress, Inflammation.

Is NCT02437396 still recruiting?

NCT02437396 is currently recruiting now. Last updated 16 March 2026.

Last reviewed 2026-03-16 · How we verify

NCT02437396

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Novel Inflammatory Biomarkers Complement 5A and Hepcidin in Patients With Gaucher Disease (GD)

Recruiting now Last updated 16 March 2026

What this trial tests

trial in Gaucher Disease Type I in 34 participants. Currently enrolling.

Timeline

1 October 2015

Primary endpoint
28 June 2026

28 June 2026

Quick facts

Lead sponsor	University of Minnesota
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	34
Start date	1 October 2015
Primary completion	28 June 2026
Estimated completion	28 June 2026
Sites	1 location across United States

Conditions studied

Gaucher Disease Type I — all drugs for Gaucher Disease Type I →
Oxidative Stress — all drugs for Oxidative Stress →
Inflammation — all drugs for Inflammation →

Sponsor

University of Minnesota

Who can join

Adults 18 to 75, any sex, with Gaucher Disease Type I or Oxidative Stress. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change in Plasma C5a Concentration
Time frame: 6 months
Outcome will be reported as the change in plasma concentration of C5a (ng/ml) from baseline to 6 months in participants with Gaucher disease type 1
Change in Plasma Hepcidin Concentration
Time frame: 6 months
Outcome will be reported as the change in plasma concentration of hepcidin (ng/ml) from baseline to 6 months in participants with Gaucher disease type 1

Sponsor's own description

The objective of this study is to evaluate oxidative stress and/or inflammation in patients with Gaucher disease type I using a series of biomarkers and correlate with measurements of currently used diagnostic biomarkers.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Antimicrobial peptides: from discovery to developmental applications.
Zhang Q. · · 2025 · cited 20× · PMID 40178173 · DOI 10.1128/aem.02115-24
Patients with Gaucher disease display systemic oxidative stress dependent on therapy status.
Kartha RV, Terluk MR, Brown R, Travis A, et al · · 2020 · cited 16× · PMID 33335836 · DOI 10.1016/j.ymgmr.2020.100667
Biological Variation in Peripheral Inflammation and Oxidative Stress Biomarkers in Individuals with Gaucher Disease.
Sahasrabudhe SA, Terluk MR, Rudser KD, Cloyd JC, et al · · 2022 · cited 6× · PMID 36012454 · DOI 10.3390/ijms23169189
Secondary Mitochondrial Dysfunction in Gaucher Disease Type I, II and III-Review of the Experimental and Clinical Evidence.
Dewsbury M, Purcell T, Hughes D, Donald A, et al · · 2025 · cited 1× · PMID 41300721 · DOI 10.3390/genes16111269

Verify or expand the search:

Other recruiting trials for Gaucher Disease Type I

Currently open trials in the same condition.

NCT06162338 — A Study of the Safety and Preliminary Efficacy of LY-M001 Injection in the Treatment of Adult Patients With Gaucher Dise · NA · recruiting

Other University of Minnesota trials

Trials by the same sponsor.

NCT02421497 — MRI Technical Development and Applications in Kidney Disease · not yet recruiting
NCT04100109 — Evaluating the Metabolic Effects of Polylactose: A Novel Prebiotic · NA · withdrawn
NCT05454306 — Anser Clavicle Pin for Surgical Management of Midshaft Clavicle Fractures · NA · withdrawn
NCT03192007 — Multi-Parametric MRI for Renal Transplantation · not yet recruiting
NCT04940533 — Pharmacokinetics of CFTR Modulators in Pregnant Individuals and in Postpartum Breastfeeding Mothers · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02437396 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Minnesota
Last refreshed: 16 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02437396.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing